Dr. Youn-hee H. Kim

Dermatology
300 Pasteur Dr, 
Stanford, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Youn-hee Kim is a Dermatologist in Stanford, California. Dr. Kim is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). Her top areas of expertise are Mycosis Fungoides, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Sezary Syndrome.

Her clinical research consists of co-authoring 151 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in CA
Hospital Affiliations
Stanford Health Care
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
Enrollment Status: Recruiting
Publish Date: October 22, 2025
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)
A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Other, Biological
Study Drugs: Interferon Gamma-1b, Pembrolizumab
Study Phase: Phase 2
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Anti-Thymocyte Globulin, Cyclosporine
Study Phase: Phase 2
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

151 Total Publications

A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification.
A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification.
Journal: Blood
Published: April 16, 2025
Similar Doctors
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Erica B. Wang
Dermatology
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Erica B. Wang
Dermatology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Erica Wang is a Dermatologist in Stanford, California. Dr. Wang has been practicing medicine for over 10 years and is rated as an Advanced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). Her top areas of expertise are Mycosis Fungoides, Melanoma, Lymphocytic Infiltrate of Jessner, and Cutaneous T-Cell Lymphoma (CTCL).

Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Bernice Y. Kwong
Dermatology
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Bernice Y. Kwong
Dermatology

Stanford Health Care

420 Broadway St, 
Redwood City, CA 
 (3.9 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bernice Kwong is a Dermatologist in Redwood City, California. Dr. Kwong is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). Her top areas of expertise are Hartsfield Syndrome, Graft Versus Host Disease (GvHD), Acute Febrile Neutrophilic Dermatosis, and DRESS Syndrome.

Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Ricardo Guerra
Dermatology
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Ricardo Guerra
Dermatology

San Rafael Medical Center

99 Montecillo Road, 
San Rafael, CA 
 (44.6 miles away)
415-444-2233
Languages Spoken:
English
Accepting New Patients

Ricardo Guerra is a Dermatologist in San Rafael, California. Dr. Guerra is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Chromoblastomycosis, Epidermodysplasia Verruciformis, Perniosis, and Chronic T-Cell Leukemia (CTCL). Dr. Guerra is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kim's expertise for a condition
ConditionClose
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile